Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6252-6258

  Goya, Masato ^a   Miyamoto, Shin'Ichi ^a   Nagai, Kanji ^b   Ohki, Yuji ^c   Nakamura, Kazuyasu ^c   Shitara, Kenya ^c   Maeda, Hiroyuki ^a   Sangai, Takafumi ^a   Kodama, Keiji ^a   Endoh, Yasushi ^a   Ishii, Genichiro ^a   Hasebe, Takahiro ^a   Yonou, Hiroyuki ^d   Hatano, Tadashi ^d   Ogawa, Yoshihide ^d   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INSULIN LIKE GROWTH FACTOR ANTIBODY; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KM1468; NEUTRALIZING ANTIBODY; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BONE METASTASIS; BONE TUMOR; CANCER CELL; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; GROWTH INHIBITION; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BALB 3T3 CELLS; BONE NEOPLASMS; CELL DIVISION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 4344591505     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0919     Document Type: Article

References (39)

1. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer (Phila) 1950;3:74-85.
2. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, Elton RA. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol 1993;72:933-6.
3. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
4. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990;66:1017-21.
5. Ishikawa S, Soloway MS, Van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141:1139-42.
6. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986;261:12665-74.
7. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994;32:73-84.
8. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20.
9. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1-6.
10. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000;36:1224-8.
11. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
12. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-53.
13. Rehault S, Monget P, Mazerbourg S, et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001;268:2960-8.
14. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996;93:7263-8.
15. Gansler T, Furlanetto R, Gramling TS, et al. Antibody to type I insulinlike growth factor receptor inhibits growth of Wilm's tumor in culture and in athymic mice. Am J Pathol 1989;135:961-6.
16. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 1994;91:2181-5.
17. Yonou H, Yokose T, Kamijo T, et al. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001;61:2177-82.
18. Navone NM, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3:2493-500.
19. Yang J, Fizazi K, Peleg S, et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 2001;61:5652-9.
20. Robert B, Peter B, Nicholas L, et al. Presence of somatostatin-28-(1-12) in hypothalamus and pancreas. Proc Natl Acad Sci USA 1982;79:917-21.
21. Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 2004;64:665-71.
22. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
23. Kato H, Faria TN, Stannard B, Roberts CTJ, LeRoith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 1993;268:2655-61.
24. Frattali AL, Pessin JE. Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-I hybrid receptors. J Biol Chemi 1993;268:7393-400.
25. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
26. Baselga J. The EGFR as a target for anticancer therapy -focus on cetuximab. Eur J Cancer 2001;37:16-22.
27. Haddad R, Lipson KE, Webb CP. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res 2001;21:4243-52.
28. Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 2002;4:20-8.
29. LeRoith D, Roberts CTJ. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
30. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
31. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin Oncol 1994;21:630-56.
32. Coleman RE, Houston S, James I, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer 1992;65:766-8.
33. Koizumi M, Yamada Y, Takiguchi T, et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995;121:542-8.
34. Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone meatastases in patients with prostate cancer. Br J Cancer 1996;77:102-6.
35. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Investig 2001;107:1235-44.
36. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997;80:1674-9.
37. Manishen WJ, Sivananthan K, Orr FW. Resorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis. Am J Pathol 1986;123:39-45.
38. Gray TK, Mohan S, Linkhart TA, Baylink DJ. Estradiol stimulates in vitro the secretion of insulin-like growth factors by the clonal osteoblastic cell line, UMR106. Biochem Biophys Res Commun 1989;158:407-12.
39. Yonou H, Aoyagi Y, Kanomata N, et al. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 2001;289:1082-7.